June 1, 2020
Japan Tobacco and its subsidiary Torii Pharmaceutical said on May 29 that JT has filed for Japan approval of the JAK inhibitor Corectim Ointment 0.25% (delgocitinib) for the treatment of atopic dermatitis in children. JT also submitted an application for...read more